Webinar ISLH di marzo 2026
10/03/2026
Prosegue l'attività didattica 2026 della International Society for Laboratory Hematology (ISLH).
Giovedì 26 marzo alle 16 italiane (11:00 AM ET), Ted Warkentin Professor Emeritus, McMaster University, Hamilton, Ontario, Canada presenterà un seminario dal titolo: "VITT explained".
Razan H. Zulkeflee Department of Hematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, sarà la moderatrice del webinar.
La partecipazione è gratuita.
Non perdete questo evento formativo!
Overview:
Vaccine/virus-induced immune thrombocytopenia and thrombosis (VITT) is an ultrarare but extreme prothrombotic disorder that features autoantibodies that target platelet factor 4 (PF4). As with immune heparin-induced thrombocytopenia (HIT), pathogenic VITT antibodies activate platelets, neutrophils, and monocytes, producing marked hypercoagulability with greatly increased risk of venous and arterial thrombosis.
Very recently, the immunopathogenesis of VITT was solved: the surprising explanation is unprecedented in the immunology literature, and thus may provide a roadmap for explaining other rare disorders that feature distinct triggers.
This lecture will summarize current concepts regarding VITT, including the important message that clinicians and laboratorians need to be on the lookout for future cases of VITT secondary to viral triggers, even as the adenoviral-vector COVID-19 vaccines that first resulted in its identification in 2021 have been discontinued from the marketplace.
Learning Objectives:
-
Describe the history of VITT.
-
Describe laboratory features of VITT.
-
Describe the spectacular immunopathogenesis of VITT (Feb 12, 2026 NEJM publication).
Notizie collegate
